PAULINA CHMIEL1,2, ALEKSANDRA SłOWIKOWSKA1,2, ŁUKASZ BANASZEK1,2, ANNA SZUMERA-CIEćKIEWICZ3, BARTłOMIEJ SZOSTAKOWSKI1, MATEUSZ J. SPAłEK1,4,*, TOMASZ ŚWITAJ1, PIOTR RUTKOWSKI1, ANNA M. CZARNECKA1
Oncology Research, Vol.32, No.7, pp. 1141-1162, 2024, DOI:10.32604/or.2024.050350
- 20 June 2024
Abstract Inflammatory myofibroblastic tumor (IMT) is a rare neoplasm with intermediate malignancy characterized by a propensity for recurrence but a low metastatic rate. Diagnostic challenges arise from the diverse pathological presentation, variable symptomatology, and lack of different imaging features. However, IMT is identified by the fusion of the anaplastic lymphoma kinase (ALK) gene, which is present in approximately 70% of cases, with various fusion partners, including ran-binding protein 2 (RANBP2), which allows confirmation of the diagnosis. While surgery is the preferred approach for localized tumors, the optimal long-term treatment for advanced or metastatic disease is difficult… More >
Login
Register
